Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Guckenberger

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 23, 2020
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and ZugR A Stahel, A Curioni-Fontecedro, S Rohrmann, et al.
Radiation Oncology (London, England)|January 26, 2022
MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)M Pavic, M Niyazi, L Wilke, et al.
The British Journal of Radiology|July 8, 2015
Stereotactic body radiotherapy for central lung tumours: Author replyS Adebahr, S Collette, E Shash, et al.
The British Journal of Radiology|April 16, 2015
LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveS Adebahr, S Collette, E Shash, et al.
EJNMMI Research|July 15, 2020
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patientsM Pavic, M Bogowicz, J Kraft, et al.
Radiation Oncology (London, England)|April 16, 2022
Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trialJ Ristau, J Hörner-Rieber, C Buchele, et al.
Frontiers in Oncology|December 12, 2022
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitorsH S Gabryś, L Basler, S Burgermeister, et al.
ESMO Open|July 24, 2025
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)J Seligmann, T Koessler, M Mauer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 19, 2024
Response to "Are roots really not worth considering?"M Guckenberger, R S Guninski, N Andratschke, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 4, 2023
ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastasesM Guckenberger, N Andratschke, C Belka, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|June 23, 2020
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and ZugR A Stahel, A Curioni-Fontecedro, S Rohrmann, et al.
Radiation Oncology (London, England)|January 26, 2022
MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)M Pavic, M Niyazi, L Wilke, et al.
The British Journal of Radiology|July 8, 2015
Stereotactic body radiotherapy for central lung tumours: Author replyS Adebahr, S Collette, E Shash, et al.
The British Journal of Radiology|April 16, 2015
LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveS Adebahr, S Collette, E Shash, et al.
EJNMMI Research|July 15, 2020
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patientsM Pavic, M Bogowicz, J Kraft, et al.
Radiation Oncology (London, England)|April 16, 2022
Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trialJ Ristau, J Hörner-Rieber, C Buchele, et al.
Frontiers in Oncology|December 12, 2022
PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitorsH S Gabryś, L Basler, S Burgermeister, et al.
ESMO Open|July 24, 2025
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)J Seligmann, T Koessler, M Mauer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 19, 2024
Response to "Are roots really not worth considering?"M Guckenberger, R S Guninski, N Andratschke, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 4, 2023
ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastasesM Guckenberger, N Andratschke, C Belka, et al.
Pageof 7